NCT00052390View on ClinicalTrials.gov

Doxorubicin and Bevacizumab in Treating Patients With Locally Recurrent or Metastatic Soft Tissue Sarcoma

PHASE2CompletedINTERVENTIONAL
Timeline

Start Date

October 31, 2002

Study Completion Date

October 31, 2005

Conditions
Sarcoma
Interventions
BIOLOGICAL

bevacizumab

DRUG

doxorubicin hydrochloride

Trial Locations (3)

10021

Memorial Sloan-Kettering Cancer Center, New York

84112

Huntsman Cancer Institute, Salt Lake City

02115

Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT00052390 - Doxorubicin and Bevacizumab in Treating Patients With Locally Recurrent or Metastatic Soft Tissue Sarcoma | Biotech Hunter | Biotech Hunter